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The Centers for Disease Control and Prevention (CDC) conducted its first formal case-
control study to better understand the causes of major birth defects in the early 1980s 
(Erickson et al., 1984). The primary purpose of the study was to evaluate the possible causal 
contribution of paternal experiences during military service in Vietnam, with particular 
emphasis on exposures to the herbicide known as “Agent Orange.” The cases and controls 
were drawn from births that occurred in the Atlanta, Georgia area, where CDC has operated 
a birth defects surveillance program since 1967. The case-control design permitted 
evaluation of a wide array of potential maternal exposures that might cause birth defects, as 
well as additional paternal influences (Erickson, 1991). For example, the study identified a 
neural tube defect preventive benefit of periconceptional multivitamin use which paved the 
way for folic acid intervention to prevent neural tube defects (Mulinare et al., 1988).
Building on this experience, the CDC launched the multicenter National Birth Defects 
Prevention Study (NBDPS) in 1997 to advance understanding of the causes of birth defects. 
Because the causes of most birth defects are unknown and might be preventable if risk 
factors are identified, the NBDPS focused on birth defects of unknown etiology (Holmes, 
1989). These included neural tube defects, congenital heart defects, orofacial clefts, limb 
deficiencies, abdominal wall defects, intestinal atresias, and other major birth defects that 
can be reliably ascertained in early infancy. One unique aspect of the NBDPS addressed the 
variability of birth defects classification across previous epidemiologic studies. In an effort 
to increase homogeneity within analytic groups of defects, clinical geneticists collaborated 
to develop classification guidelines that were applied across the study sites (Rasmussen et 
al., 2003). This and other efforts to coordinate work and maintain consistent methodology 
across participating Centers in multiple states, improved the power of NBDPS to identify 
potential causes of specific birth defects despite the relatively low prevalence of each 
individual defect type. This is particularly important for studying the epidemiology of birth 
defects because to date, exposures identified as causing birth defects have a relatively 
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specific impact on one or a few types of birth defects rather than increasing the risk of all 
birth defects (Tinker, Gilboa, et al., 2015). The NBDPS methods and final counts of data 
collected are summarized by Reefhuis et al. in this issue (Reefhuis et al., 2015), and the 
strengths and weaknesses of the NBDPS have been assessed (Dolk, 2015).
In addition to the statistical power gained by taking a multicenter approach, the NBDPS 
provided a diverse sample in terms of geographic residence, race/ethnicity, and 
socioeconomic status. The NBDPS has also benefited from the tremendous epidemiological, 
clinical, and biological expertise contributed by each Center. Across the period of the study, 
the CDC Center in Georgia and the funded Centers in Arkansas, California, Iowa, 
Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah have each 
contributed birth defects expertise and have also developed a new cadre of birth defects 
researchers including many masters and doctoral students trained in NBDPS data analysis. 
NBDPS data have provided training to a wide range of students in MPH, doctoral, 
postdoctoral, and other fellowship training programs. As of December 2014, over 50 trainees 
had published one or more papers using NBDPS data, including at least 27 doctoral students 
who used this data for their dissertation. In addition, the careful data collection and extensive 
quality control efforts at each site have greatly contributed to the value of the NBDPS and 
the resulting data.
Folic acid fortification is a major public health success story that resulted from both 
observational data and randomized controlled trials, and has led to the prevention of 
approximately 1,300 neural tube defects per year since 1998 (Williams et al., 2015). An 
aspirational goal of the NBDPS was to identify the next folic acid-type risk factor that could 
be rapidly translated into birth defects prevention efforts of a similar magnitude. The 
NBDPS has yielded an extensive number of publications identifying potentially risky 
exposures before and during pregnancy as well as publications that offer some reassurance 
about an apparent lack of risk. While no single exposure with the prevention potential of 
folic acid has been identified to date, the NBDPS has made important contributions to our 
understanding of the potential effect of prepregnancy obesity, opioid analgesics, antibacterial 
medications, assisted reproductive technology, antidepressant medications and other 
pregnancy exposures (Alwan and Chambers, 2015). Findings from the NBDPS have served 
a confirmatory role in some cases, such as adding evidence to a prior link between smoking 
and orofacial clefts that resulted in the conclusion from the 2014 Surgeon General’s Report 
that smoking was a cause of some orofacial clefts (US DHHS, 2014). In other instances, 
NBDPS has generated hypotheses about relatively new exposures with unknown 
teratogenicity such as the antidepressant venlafaxine (Polen et al., 2013). NBDPS has 
encouraged the development of collaborations between Centers as well as with outside 
investigators. There is not a public use version of the data available because de-identifying 
the data would remove critical information that is needed in most analyses; how- ever, there 
is a process in place for outside investigators to propose research plans and use the data 
either as part of a special agreement or under controlled conditions as specified in the 
protocol (http://www.cdc.gov/ncbddd/documents/nbdpsprotocolrev4-10.pdf). The successor 
to the NBDPS is the Birth Defects Study To Explore Pregnancy exposureS, or BD-STEPS, 
and this study builds on the findings and the lessons learned from NBDPS (Carmichael et 
al., 2015).
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This special issue highlights some of the contributions of NBDPS and provides various 
perspectives on these contributions, describes some methods used for data exploration, 
assesses the changing landscape of birth defects epidemiology during the time period of the 
study, and points to future opportunities. As the initial architects of the NBDPS, we take 
great pride in reflecting on the many accomplishments to date and are confident that the 
NBDPS will continue to be a valuable data source for identifying potential environmental 
and genetic risk factors for birth defects in the years to come. Many of the early publications 
from the NBDPS can now be replicated using independent data from the latter years of the 
study and the accumulation of data on more rare birth defects offers a first opportunity to 
study their epidemiology. Researchers around the world can further explore the many 
hypotheses generated by analyses of the rich NBDPS data and further elucidate birth defects 
etiology with the ultimate goal of prevention.
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